Company Profile
SAB Biotherapeutics Stock Price, News & Catalysts
- Ticker:
- SABS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.50 USD (+3.24%)
Close
Last updated: September 17, 2026
266M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, SABS closed up 3.24% at $3.50. No new same-company headline was identified in the current news window.
Company overview
Fully Human Polyclonal Antibodies
SAB Biotherapeutics uses genetically engineered cattle to produce large quantities of fully human polyclonal antibodies.
SAB-142
SAB-142 is a human anti-thymocyte immunoglobulin intended to preserve insulin-producing beta-cell function in newly diagnosed type 1 diabetes.
SAFEGUARD
The registrational Phase 2b SAFEGUARD study enrolls children and adults within 100 days of Stage 3 type 1 diabetes diagnosis.
Future catalysts
- SAFEGUARD enrollment is expected to complete by year-end 2026.
- Topline SAFEGUARD data are expected in the second half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of SAB Biotherapeutics (SABS)?
SAB Biotherapeutics (SABS) most recently closed at 3.50 USD, a +3.24% move versus the previous session.
What is the market cap of SAB Biotherapeutics (SABS)?
SAB Biotherapeutics currently has a market capitalization of 266M USD on BioPharmSignal.
What does SAB Biotherapeutics do?
Fully Human Polyclonal Antibodies SAB Biotherapeutics uses genetically engineered cattle to produce large quantities of fully human polyclonal antibodies. SAB-142 SAB-142 is a human anti-thymocyte immunoglobulin intended to preserve insulin-producing beta-cell function in newly diagnosed type 1 diabetes. SAFEGUARD The registrational Phase 2b SAFEGUARD study...
On which exchange is SABS stock listed?
SAB Biotherapeutics (SABS) is associated with NASDAQ, United States, Biopharma.
What is SAB-142?
SAB-142 SAB-142 is a human anti-thymocyte immunoglobulin intended to preserve insulin-producing beta-cell function in newly diagnosed type 1 diabetes.
Which conditions is SAB Biotherapeutics targeting with SAB-142?
SAB Biotherapeutics is associated with diabetes, genetic disease based on its company overview and current catalyst commentary.
How does SAB Biotherapeutics describe recent progress with SAB-142?
SAFEGUARD enrollment is expected to complete by year-end 2026. Topline SAFEGUARD data are expected in the second half of 2027.
What is Fully?
Fully Human Polyclonal Antibodies SAB Biotherapeutics uses genetically engineered cattle to produce large quantities of fully human polyclonal antibodies.